medalphabetМедицинский алфавитMedical alphabet2078-56312949-2807ООО «Альфмед»10.33667/2078-5631-2022-3-23-28medalphabet-2541Research ArticleСтатьиCOVID-19 в структуре факторов риска когнитивных нару шений, способы коррекцииCOVID-19 in structure of risk factors for cognitive impairment, methods of correctionhttps://orcid.org/0000-0001-6747-3476КамчатновП. Р.KamchatnovP. R.

Камчатнов Павел Рудольфович, д.м.н., проф. кафедры неврологии, нейрохирургии и медицинской генетики лечебного факультета

Москва

Kamchatnov Pavel R., DM Sci (habil.), professor at Dept of Neurology, Neurosurgery and Medical Genetics, Faculty of Medicine

Moscow

pavkam7@gmail.comhttps://orcid.org/0000-0001-6018-6327ЧереминР. А.ChereminR. A.

Черемин Роман Авенирович, к.м.н., гл. врач

Москва

Cheremin Roman A., PhD Med, chief physician

Moscow

https://orcid.org/0000-0002-6019-4981СкипетроваЛ. А.SkipetrovaL. A.

Скипетрова Людмила Александровна, зам. гл. врача

Москва

Skipetrova Lyudmila A., deputy chief physician

Moscow

https://orcid.org/0000-0002-5221-0478НиконоваА. А.NikonovaA. A.

Никонова Анастасия Алексеевна, к.м.н., ассистент кафедры неврологии, нейрохирургии и медицинской генетики лечебного факультета

Москва

Nikonova Anastasia A., PhD Med, assistant at Dept of Neurology, Neurosurgery and Medical Genetics, Faculty of Medicine

Moscow

https://orcid.org/0000-0001-6418-8063ПышкинаЛ. А.PyshkinaL. A.

Пышкина Людмила Ильинична, д.м.н., проф. кафедры неврологии, нейрохирургии и медицинской генетики лечебного факультета

Москва

Pyshkina Lyudmila I., DM Sci (habil.), professor at Dept of Neurology, Neurosurgery and Medical Genetics, Faculty of Medicine

Moscow

ФБГОУ ВО «Российский национальный исследовательский медицинский университет имени Н. И. Пирогова» Минздрава РоссииРоссияRussian National Research Medical University n.a. N. I. PirogovRussian FederationГБУЗ «Центр патологии речи и нейрореабилитации Департамента здравоохранения Москвы»РоссияCentre of Speech Pathology and NeurorehabilitationRussian Federation20221504202203Современная поликлиника (1)2328Copyright © Камчатнов П.Р., Черемин Р.А., Скипетрова Л.А., Никонова А.А., Пышкина Л.А., 20222022Камчатнов П.Р., Черемин Р.А., Скипетрова Л.А., Никонова А.А., Пышкина Л.А.Kamchatnov P.R., Cheremin R.A., Skipetrova L.A., Nikonova A.A., Pyshkina L.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-alphabet.com/jour/article/view/2541

Цереброваскулярные расстройства – одна из основных причин формирования когнитивных нарушений. Понимание причины сосудистого поражения головного мозга, установление имеющихся факторов риска позволяют выбрать оптимальную тактику лечения и замедление прогрессирования когнитивных нарушений. В статье рассматриваются сведения о факторах риска развития когнитивных нарушений: возраст, уровень образования, социальная изоляция и отсутствие физической активности, избыточное потребление алкоголя, курение, пребывание в условиях загрязненного воздуха, артериальная гипертензия, утрата слуха, черепно-мозговая травма, сахарный диабет, депрессия, цереброваскулярные заболевания, болезнь Альцгеймера, генетическая предрасположенность. Приведены сведения о возможном влиянии COVID-19 на развитие и прогрессирование когнитивных нарушений. Рассмотрены возможности нейрометаболических препаратов в лечении когнитивных нарушений. Приведены результаты анализа опыта применения препарата цитиколин (Нооцил) при лечении больных с когнитивными нарушениями, отмечены возможные преимущества назначения Нооцила в виде раствора дли перорального применения.

Cerebrovascular disorders are one of the main causes of cognitive impairment. Understanding the cause of vascular brain damage, establishing the existing risk factors allow choosing the optimal treatment strategy and slowing the progression of cognitive impairment. The article discusses information about risk factors for cognitive impairment: age, level of education, social isolation and lack of physical activity, excessive alcohol consumption, smoking, exposure to polluted air, hypertension, hearing loss, traumatic brain injury, diabetes mellitus, depression, cerebrovascular diseases, Alzheimer’s disease, genetic predisposition. Information is provided on the possible impact of COVID-19 on the development and progression of cognitive impairment. The possibilities of neurometabolic drugs in the treatment of cognitive disorders are considered. The results of the analysis of the experience of using the drug citicoline (Noocil) in the treatment of patients with cognitive impairment are presented, the possible advantages of prescribing Noocil in the form of a solution for oral administration are noted.

когнитивные нарушенияфакторы рискаCOVID-19постковидный синдромлечениеприверженностьцитиколинНооцилcognitive impairmentrisk factorsCOVID-19postcovid syndrometreatmentadherenceciticolineNoocilReferencesWorld Health Organization (WHO) and Alzheimer disease international. Dementia: A Public Health Priority; 2012.World Health Organization (WHO) and Alzheimer disease international. Dementia: A Public Health Priority; 2012.Brookmeyer R., Evans D.A., Hebert L., et al. National estimates of the prevalence of Alzheimer’s disease in the United States. Alzheimers Dement. 2011; 7 (1): 61–73. DOI: 10.1016/j.jalz.2010.11.00.Brookmeyer R., Evans D.A., Hebert L., et al. National estimates of the prevalence of Alzheimer’s disease in the United States. Alzheimers Dement. 2011; 7 (1): 61–73. DOI: 10.1016/j.jalz.2010.11.00.Prince M, Knapp M, Guerchet M, et al. Dementia UK: update. Alzheimer’s. Society. 2014Prince M, Knapp M, Guerchet M, et al. Dementia UK: update. Alzheimer’s. Society. 2014Wittenberg R, Knapp M, Hu B, et al. The costs of dementia in England. Int J Geriatr Psychiatry. 2019; 34 (7): 1095–1103. DOI: 10.1002/gps.5113.Wittenberg R, Knapp M, Hu B, et al. The costs of dementia in England. Int J Geriatr Psychiatry. 2019; 34 (7): 1095–1103. DOI: 10.1002/gps.5113.Alzheimer’s Society. Dementia UK Update. 2014.Alzheimer’s Society. Dementia UK Update. 2014.McGilton K.S., Davis A.M., Naglie G., et al. Evaluation of patient-centered rehabilitation model targeting older persons with a hip fracture, including those with cognitive impairment. BMC Geriatr. 2013; 13 (1): 1–8. DOI: 10.1186/1471–2318–13–136.McGilton K.S., Davis A.M., Naglie G., et al. Evaluation of patient-centered rehabilitation model targeting older persons with a hip fracture, including those with cognitive impairment. BMC Geriatr. 2013; 13 (1): 1–8. DOI: 10.1186/1471–2318–13–136.Draper B. Understanding Alzheimer’s disease and other dementias: Jessica Kingsley Publishers; 2013.Draper B. Understanding Alzheimer’s disease and other dementias: Jessica Kingsley Publishers; 2013.Altomare D., Molinuevo J.L, Ritchie C., et al. Brain Health Services: Organization, structure and challenges for implementation. A user manual for Brain Health Services – Part 1 of 6. Alzheimers Res Ther. 2021.Altomare D., Molinuevo J.L, Ritchie C., et al. Brain Health Services: Organization, structure and challenges for implementation. A user manual for Brain Health Services – Part 1 of 6. Alzheimers Res Ther. 2021.Livingston G., Sommerlad A., Orgeta V., et al. Dementia prevention, intervention, and care. Lancet. 2017; 390 (10113): 2673–2734. DOI: 10.1016/S0140–6736(17)31363–6.Livingston G., Sommerlad A., Orgeta V., et al. Dementia prevention, intervention, and care. Lancet. 2017; 390 (10113): 2673–2734. DOI: 10.1016/S0140–6736(17)31363–6.Livingston G., Huntley J., Sommerlad A., et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet. 2020; 396 (10248): 413–446. DOI: 10.1016/S0140–6736(20)30367–6.Livingston G., Huntley J., Sommerlad A., et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet. 2020; 396 (10248): 413–446. DOI: 10.1016/S0140–6736(20)30367–6.Камчатнов П.Р. Когнитивный резерв, когнитивные нарушения и возможность их медикаментозной коррекции. Журн. неврол. и психиат. им. С.С. Корсакова. 2014; 4: 52–56.Kamchatnov P.R. Cognitive reserve, cognitive disorders and the possibility of their drug correction. S.S. Korsakov Journal of Neurology and Psychiatry = Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2014; 4: 52–56. (In Russ.).Arenaza-Urquijo E.M., Wirth M., Chételat G. Cognitive reserve and lifestyle: moving towards preclinical Alzheimer’s disease. Front Aging Neurosci. 2015; 7: т134. DOI: 10.3389/fnagi.2015.00134.Arenaza-Urquijo E.M., Wirth M., Chételat G. Cognitive reserve and lifestyle: moving towards preclinical Alzheimer’s disease. Front Aging Neurosci. 2015; 7: т134. DOI: 10.3389/fnagi.2015.00134.Peelle J.E., Troiani V., Grossman M., Wingfield A. Hearing loss in older adults affects neural systems supporting speech comprehension. J Neurosci. 2011; 31т(35): 12638–12643. DOI: 10.1523/jneurosci.2559–11.2011.Peelle J.E., Troiani V., Grossman M., Wingfield A. Hearing loss in older adults affects neural systems supporting speech comprehension. J Neurosci. 2011; 31т(35): 12638–12643. DOI: 10.1523/jneurosci.2559–11.2011.Hughes T. F., Ganguli M. Modifiable midlife risk factors for late-life cognitive impairment and dementia. Curr Psychiatry Rev. 2009; 5 (2): 73–92. DOI: 10.2174/157340009788167347.Hughes T. F., Ganguli M. Modifiable midlife risk factors for late-life cognitive impairment and dementia. Curr Psychiatry Rev. 2009; 5 (2): 73–92. DOI: 10.2174/157340009788167347.Leon B.M., Maddox T.M. Diabetes and cardiovascular disease: Epidemiology, biological mechanisms, treatment recommendations and future research. World J Diabetes. 2015; 6: 1246–1258. DOI: 10.4239/wjd.v6.i13.1246.Leon B.M., Maddox T.M. Diabetes and cardiovascular disease: Epidemiology, biological mechanisms, treatment recommendations and future research. World J Diabetes. 2015; 6: 1246–1258. DOI: 10.4239/wjd.v6.i13.1246.Kivimäki M., Singh-Manoux A., Pentti J., et al. Physical inactivity, cardiometabolic disease, and risk of dementia: an individual-participant meta-analysis. BMJ. 2019; 365: 1495. DOI: 10.1136/bmj.l1495.Kivimäki M., Singh-Manoux A., Pentti J., et al. Physical inactivity, cardiometabolic disease, and risk of dementia: an individual-participant meta-analysis. BMJ. 2019; 365: 1495. DOI: 10.1136/bmj.l1495.Shalev D., Arbuckle M.R. Metabolism and memory: obesity, diabetes, and dementia. Biol Psychiatry. 2017; 82 (11): e81–e83. DOI: 10.1016/j.biopsych.2017.09.025.Shalev D., Arbuckle M.R. Metabolism and memory: obesity, diabetes, and dementia. Biol Psychiatry. 2017; 82 (11): e81–e83. DOI: 10.1016/j.biopsych.2017.09.025.Чукаева И.И., Орлова Н.В., Алешкин В.А., и др. Воспалительные реакции у больных ишемической болезнью сердца с сопутствующими ожирением и сахарным диабетом 2-го типа. Клиническая медицина. 2008. Т. 86. № 1. С. 27–30Chukaeva I.I., Orlova N.V., Aleshkin V.A., i dr. Vospalitel’nye reakcii u bol’nyh ishemicheskoj bolezn’yu serdca s soputstvuyushchimi ozhireniem i saharnym diabetom 2-go tipa. Klinicheskaya medicina. 2008. T. 86. No. 1. P. 27–30.Чукаева И.И., Орлова Н.В., Хавка Н.Н., Клепикова М.В. Изучение факторов воспаления у больных с метаболическим синдромом. Лечебное дело. 2010. № 4. С. 50–56Chukaeva I.I., Orlova N.V., Havka N.N., Klepikova M.V. Izuchenie faktorov vospaleniya u bol’nyh s metabolicheskim sindromom. Lechebnoe delo. 2010. No. 4. P. 50–56.Peters R., Ee N., Peters J., et al. Air pollution and dementia: a systematic review. J Alzheimers Dis. 2019; 70 (s1): P. 145–163. DOI: 10.3233/JAD-180631.Peters R., Ee N., Peters J., et al. Air pollution and dementia: a systematic review. J Alzheimers Dis. 2019; 70 (s1): P. 145–163. DOI: 10.3233/JAD-180631.Cacioppo J.T., Hawkley L.C., Norman G.J., Berntson G.G. Social isolation. Ann NY Acad Sci. 2011; 1231 (1): 17–22. DOI: 10.1111/j.1749–6632.2011.06028.xCacioppo J.T., Hawkley L.C., Norman G.J., Berntson G.G. Social isolation. Ann NY Acad Sci. 2011; 1231 (1): 17–22. DOI: 10.1111/j.1749–6632.2011.06028.xKobayashi L.C., Steptoe A. Social isolation, loneliness, and health behaviors at older ages: longitudinal cohort study. Ann Behav Med. 2018; 52 (7): 582–593. DOI: 10.1093/abm/kax033.Kobayashi L.C., Steptoe A. Social isolation, loneliness, and health behaviors at older ages: longitudinal cohort study. Ann Behav Med. 2018; 52 (7): 582–593. DOI: 10.1093/abm/kax033.Kunkle B.W., Grenier-Boley B., Sims R., et al. Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing. Nat Genet. 2019; 51 (3): 414–430. DOI: 10.1038/s41588–019–0358–2.Kunkle B.W., Grenier-Boley B., Sims R., et al. Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing. Nat Genet. 2019; 51 (3): 414–430. DOI: 10.1038/s41588–019–0358–2.van der Lee S.J., Wolters F.J., Ikram M.K., et al. The effect of APOE and other common genetic variants on the onset of Alzheimer’s disease and dementia: a community-based cohort study. Lancet Neurol. 2018; 17: 434–444. DOI: 10.1016/S1474–4422(18)30053-X.van der Lee S.J., Wolters F.J., Ikram M.K., et al. The effect of APOE and other common genetic variants on the onset of Alzheimer’s disease and dementia: a community-based cohort study. Lancet Neurol. 2018; 17: 434–444. DOI: 10.1016/S1474–4422(18)30053-X.Reiman E. M., Arboleda-Velasquez J.F., Quiroz Y. T., et al. Exceptionally low likelihood of Alzheimer’s dementia in APOE 2 homozygotes from a 5,000-person neuropathological study. Nat Commun. 2020; 11 (1): 667. DOI: 10.1038/s41467–019–14279–8.Reiman E. M., Arboleda-Velasquez J.F., Quiroz Y. T., et al. Exceptionally low likelihood of Alzheimer’s dementia in APOE 2 homozygotes from a 5,000-person neuropathological study. Nat Commun. 2020; 11 (1): 667. DOI: 10.1038/s41467–019–14279–8.Genin E., Hannequin D., Wallon D., et al. APOE and Alzheimer disease: a major gene with semi-dominant inheritance. Mol Psychiatry. 2011; 16 (9): 903–907. DOI: 10.1038/mp.2011.52.Genin E., Hannequin D., Wallon D., et al. APOE and Alzheimer disease: a major gene with semi-dominant inheritance. Mol Psychiatry. 2011; 16 (9): 903–907. DOI: 10.1038/mp.2011.52.Myers R.H., Schaefer E.J., Wilson P.W., et al. Apolipoprotein E epsilon4 association with dementia in a population-based study: The Framingham study. Neurology. 1996; 46 (3): 673–677. DOI: 10.1212/WNL.46.3.673.Myers R.H., Schaefer E.J., Wilson P.W., et al. Apolipoprotein E epsilon4 association with dementia in a population-based study: The Framingham study. Neurology. 1996; 46 (3): 673–677. DOI: 10.1212/WNL.46.3.673.Slooter A.J., Cruts M., Kalmijn S., et al. Risk estimates of dementia by apolipoprotein E genotypes from a population-based incidence study: the Rotterdam Study. Arch Neurol. 1998; 55 (7): 964–968. DOI: 10.1001/archneur.55.7.964Slooter A.J., Cruts M., Kalmijn S., et al. Risk estimates of dementia by apolipoprotein E genotypes from a population-based incidence study: the Rotterdam Study. Arch Neurol. 1998; 55 (7): 964–968. DOI: 10.1001/archneur.55.7.964Bateman R.J., Aisen P.S., De Strooper B., et al. Autosomal-dominant Alzheimer’s disease: a review and proposal for the prevention of Alzheimer’s disease. Alzheimers Res Ther. 2011; 3 (1): 1–1. DOI: 10.1186/alzrt59Bateman R.J., Aisen P.S., De Strooper B., et al. Autosomal-dominant Alzheimer’s disease: a review and proposal for the prevention of Alzheimer’s disease. Alzheimers Res Ther. 2011; 3 (1): 1–1. DOI: 10.1186/alzrt59Rossor M.N., Fox N.C., Mummery C.J., et al. The diagnosis of young-onset dementia. Lancet Neurol. 2010; 9 (8): 793–806. DOI: 10.1016/S1474–4422(10)70159–9.Rossor M.N., Fox N.C., Mummery C.J., et al. The diagnosis of young-onset dementia. Lancet Neurol. 2010; 9 (8): 793–806. DOI: 10.1016/S1474–4422(10)70159–9.Ryman D.C., Acosta-Baena N., Aisen P.S., et al. And the Dominantly Inherited Alzheimer Network Symptom onset in autosomal dominant Alzheimer disease: a systematic review and meta-analysis. Neurology. 2014; 83 (3): 253–260. DOI: 10.1212/WNL.0000000000000596.Ryman D.C., Acosta-Baena N., Aisen P.S., et al. And the Dominantly Inherited Alzheimer Network Symptom onset in autosomal dominant Alzheimer disease: a systematic review and meta-analysis. Neurology. 2014; 83 (3): 253–260. DOI: 10.1212/WNL.0000000000000596.Pérez-Rodríguez P., Ganz F., Torralba R., et al. Impact of Social Isolation Due to COVID-19 on Health in Older People: Mental and Physical Effects and Recommendations. J. Nutr. Health Aging. 2020; 24: 938–947. DOI: 10.1007/s12603–020–1469–2.Pérez-Rodríguez P., Ganz F., Torralba R., et al. Impact of Social Isolation Due to COVID-19 on Health in Older People: Mental and Physical Effects and Recommendations. J. Nutr. Health Aging. 2020; 24: 938–947. DOI: 10.1007/s12603–020–1469–2.Méndez-Giménez A. COVID-19, Psychological Well-being and Physical Activity Levels in Older Adults During the Nationwide Lockdown in Spain. Am.J. Geriatr. Psychiatry. 2020; 28: 1146–1155. DOI: 10.1016/j.jagp.2020.08.007.Méndez-Giménez A. COVID-19, Psychological Well-being and Physical Activity Levels in Older Adults During the Nationwide Lockdown in Spain. Am.J. Geriatr. Psychiatry. 2020; 28: 1146–1155. DOI: 10.1016/j.jagp.2020.08.007.Hardan L., Filtchev D., Kassem R., et al. COVID-19 and Alzheimer’s Disease: A Literature Review. Medicina (Kaunas). 2021 Oct 25; 57 (11): 1159. DOI: 10.3390/medicina57111159.Hardan L., Filtchev D., Kassem R., et al. COVID-19 and Alzheimer’s Disease: A Literature Review. Medicina (Kaunas). 2021 Oct 25; 57 (11): 1159. DOI: 10.3390/medicina57111159.Mok V.C., Pendlebury S., Wong A, et al. Tackling challenges in care of Alzheimer’s disease and other dementias amid the COVID-19 pandemic, now and in the future. Alzheimers Dement. 2020; 16: 1571–1581. DOI: 10.1002/alz.12143.Mok V.C., Pendlebury S., Wong A, et al. Tackling challenges in care of Alzheimer’s disease and other dementias amid the COVID-19 pandemic, now and in the future. Alzheimers Dement. 2020; 16: 1571–1581. DOI: 10.1002/alz.12143.Zhou F., Yu T., Du R., et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet. 2020; 28: 1054–1062. DOI: 10.1016/S0140–6736(20)30566–3.Zhou F., Yu T., Du R., et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet. 2020; 28: 1054–1062. DOI: 10.1016/S0140–6736(20)30566–3.Yang X., Yu Y., Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: A single-centered, retrospective, observational study. Lancet Respir. Med. 2020; 8: 475–481. DOI: 10.1016/S2213–2600(20)30079–5.Yang X., Yu Y., Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: A single-centered, retrospective, observational study. Lancet Respir. Med. 2020; 8: 475–481. DOI: 10.1016/S2213–2600(20)30079–5.Ye Q., Wang B., Mao J. The pathogenesis and treatment of the ‘Cytokine Storm’ in COVID-19. J. Infect. 2020; 80: 607–613. DOI: 10.1016/j.jinf.2020.03.037.Ye Q., Wang B., Mao J. The pathogenesis and treatment of the ‘Cytokine Storm’ in COVID-19. J. Infect. 2020; 80: 607–613. DOI: 10.1016/j.jinf.2020.03.037.Numbers K., Brodaty H. The effects of the COVID-19 pandemic on people with dementia. Nat. Rev. Neurol. 2021; 17: 69–70. DOI: 10.1038/s41582–020–00450-z.Numbers K., Brodaty H. The effects of the COVID-19 pandemic on people with dementia. Nat. Rev. Neurol. 2021; 17: 69–70. DOI: 10.1038/s41582–020–00450-z.Wang H., Li T., Barbarino P, et al. Dementia care during COVID-19. Lancet. 2020; 395: 1190–1191. DOI: 10.1016/S0140–6736(20)30755–8.Wang H., Li T., Barbarino P, et al. Dementia care during COVID-19. Lancet. 2020; 395: 1190–1191. DOI: 10.1016/S0140–6736(20)30755–8.Palmer K., Monaco A., Kivipelto M, et al. The potential long-term impact of the COVID-19 outbreak on patients with non-communicable diseases in Europe: Consequences for healthy ageing. Aging Clin. Exp. Res. 2020; 32: 1189–1194. DOI: 10.1007/s40520–020–01601–4.Palmer K., Monaco A., Kivipelto M, et al. The potential long-term impact of the COVID-19 outbreak on patients with non-communicable diseases in Europe: Consequences for healthy ageing. Aging Clin. Exp. Res. 2020; 32: 1189–1194. DOI: 10.1007/s40520–020–01601–4.Palmieri L., Vanacore N., Donfrancesco C, et al. Clinical characteristics of hospitalized individuals dying with COVID-19 by age Group in Italy. J. Gerontol. A Biol. Sci. Med. Sci. 2020; 75: 1796–1800. DOI: 10.1093/gerona/glaa146.Palmieri L., Vanacore N., Donfrancesco C, et al. Clinical characteristics of hospitalized individuals dying with COVID-19 by age Group in Italy. J. Gerontol. A Biol. Sci. Med. Sci. 2020; 75: 1796–1800. DOI: 10.1093/gerona/glaa146.Boutoleau-Bretonnière C., Pouclet-Courtemanche H., Gillet A., et al. The Effects of Confinement on Neuropsychiatric Symptoms in Alzheimer’s Disease During the COVID-19 Crisis. J. Alzheimers Dis. 2020; 76: 41–47. DOI: 10.3233/JAD-200604.Boutoleau-Bretonnière C., Pouclet-Courtemanche H., Gillet A., et al. The Effects of Confinement on Neuropsychiatric Symptoms in Alzheimer’s Disease During the COVID-19 Crisis. J. Alzheimers Dis. 2020; 76: 41–47. DOI: 10.3233/JAD-200604.Chiao C.-Y., Wu H.-S., Hsiao C.-Y. Caregiver burden for informal caregivers of patients with dementia: A systematic review. Int. Nurs. Rev. 2015; 62: 340–350. DOI: 10.1111/inr.12194.Chiao C.-Y., Wu H.-S., Hsiao C.-Y. Caregiver burden for informal caregivers of patients with dementia: A systematic review. Int. Nurs. Rev. 2015; 62: 340–350. DOI: 10.1111/inr.12194.Захаров В. В. Постковидный синдром глазами невролога. Поведенческая неврология. 2021; 2: 14–22.Zakharov VV. Postcovid syndrome through the eyes of a neurologist. Behavioral neurology. 2021; 2: 14–22. (In Russ.). https://doi.org/10.46393/2712–9675_2021_2_14_22Камчатнов П.Р., Соловьева Э.Ю., Хасанова Д.Р., Фатеева В.В. Астенические и когнитивные нарушения у пациентов, перенесших COVID-19. РМЖ. Медицинское обозрение. 2021; 5 (10): 636–641. https://doi.org/10.32364/2587–6821–2021–5–10–636–641Kamchatnov P.R., Solov’eva E. Yu., Khasanova D.R., Fateeva V.V. Asthenic and cognitive disorders after the COVID-19 infection. Russian Medical Inquiry. 2021; 5 (10): 636–641 (in Russ.). https://doi.org/10.32364/2587–6821–2021–5–10–636–641Helms J., Kremer S., Merdji H, et al. Neurologic features in severe SARS-CoV-2 infection. N. Engl. J. Med. 2020; 382: 2268–2270. DOI: 10.1056/NEJMc2008597.Helms J., Kremer S., Merdji H, et al. Neurologic features in severe SARS-CoV-2 infection. N. Engl. J. Med. 2020; 382: 2268–2270. DOI: 10.1056/NEJMc2008597.Иванова Г.Е., Мельникова Е.В., Левин О.С. и др. Резолюция Совета экспертов. Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски. 2020; 120 (8–2): 81–87. https://doi.org/10.17116/jnevro202012008281Ivanova G.E., Melnikova E.V., Levin O.S., et al. Current issues in the rehabilitation of stroke patients against the background of a new coronavirus infection (COVID-19). Resolution of the Council of Experts. S.S. Korsakov Journal of Neurology and Psychiatry = Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2020; 120 (8–2): 81–87. (In Russ.). https://doi.org/10.17116/jnevro202012008281Стариков П. В., Камчатнов П. Р., Леушин Е. К. Открытое сравнительное исследование применения препарата Эврин при тревожных и когнитивных нарушениях у стационарных больных COVID-19. Эффективная фармакотерапия. 2021; 17; 29: 6–13. https://doi.org/10.33978/2307–3586–2021–17–29–6–13Starikov P.V., Kamchatnov P.R., Leushin E.K. An open comparative study of the use of the drug Evrin in anxiety and cognitive disorders in inpatient patients with COVID-19. Effective pharmacotherapy. 2021; 17; 29: 6–13. (In Russ.). https://doi.org/10.33978/2307–3586–2021–17–29–6–13Adibhalta R. M. Citicoline: neuroprotective mechanisms in cerebral ischemia. J. Neurochem. 2002; 80: 12–23.Adibhalta R. M. Citicoline: neuroprotective mechanisms in cerebral ischemia. J. Neurochem. 2002; 80: 12–23.Одинак М.М., Вознюк И.А. Роль экзогенного холина в защите и восстановлении мозгового вещества при инсульте. Качество жизни. Медицина. 2007; 4 (21): 2–9.Odinak M.M., Voznyuk I.A. The role of exogenous choline in the protection and restoration of brain matter in stroke. Quality of life. Medicine. 2007; 4 (21): 2–9. (In Russ.).Adibhatla R.M., Hatcher J.F. Cytidine 5’diphosphocholine (CDP-choline) in stroke and other CNS disorders. Neurochem Res. 2005; 30: 15–23.Adibhatla R.M., Hatcher J.F. Cytidine 5’diphosphocholine (CDP-choline) in stroke and other CNS disorders. Neurochem Res. 2005; 30: 15–23.Гусев Е.И., Батышева Т.Т., Бойко А.Н. и др. Результаты применения цераксона (цитиколин) у больных с острым инсультом. Медицина критических состояний. 2010; 1: 45–51.Gusev E. I., Batysheva T. T., Boyko A. N. et al. Results of the use of ceraxone (citicoline) in patients with acute stroke. Critical Condition Medicine. 2010; 1: 45–51. (In Russ.).Murphy E.J., Horrocks L.A. CDP-choline, CDP-ethanolamine, lipid metabolism and disorders of the central nervous system. Phopspholipids and Signal Transmission. Berlin: Spriger-Verlag. 1993: 353–72.Murphy E.J., Horrocks L.A. CDP-choline, CDP-ethanolamine, lipid metabolism and disorders of the central nervous system. Phopspholipids and Signal Transmission. Berlin: Spriger-Verlag. 1993: 353–72.Gareri P., Castagna A., Cotroneo A.M., et al. The role of citicoline in cognitive impairment: pharmacological characteristics, possible advantages, and doubts for an old drug with new perspectives. Clin Interv Aging. 2015 Sep 3; 10: 1421–9. DOI: 10.2147/CIA.S87886.Gareri P., Castagna A., Cotroneo A.M., et al. The role of citicoline in cognitive impairment: pharmacological characteristics, possible advantages, and doubts for an old drug with new perspectives. Clin Interv Aging. 2015 Sep 3; 10: 1421–9. DOI: 10.2147/CIA.S87886.Spiers P.A., Myers D., Hochanadel G. et al. Citicoline improves verbal memory in aging. Arch Neurol 1996; 53: 441–48.Spiers P.A., Myers D., Hochanadel G. et al. Citicoline improves verbal memory in aging. Arch Neurol 1996; 53: 441–48.Белова Д.А., Машин В.В., Дудиков К.М. и др. Наблюдательная программа по оценке эффективности комплексной терапии препаратами кортексин и рекогнан (цитиколин) когнитивных нарушений у пациентов с хронической цереброваскулярной патологией. Журнал неврологии и психиатрии им. С.С. Корсакова. 2019; 119 (2): 35–38. https://doi.org/10.17116/jnevro201911902135Belova L.A., Mashin V.V., Dudikov E.M., et al. A multicenter observation study of the efficacy of cortexin and recognan (citicoline) in the treatment of cognitive impairments in chronic cerebrovascular pathology. S. S. Korsakov Journal of Neurology and Psychiatry = Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2019; 119 (2): 35–38. (In Russ.). https://doi.org/10.17116/jnevro201911902135Wu S., Kutlubaev M.A., Chun H.Y., et al. Interventions for post-stroke fatigue. Cochrane Database Syst Rev. 2015 Jul 2; 2015 (7): CD007030. DOI: 10.1002/14651858.CD007030.pub3Wu S., Kutlubaev M.A., Chun H.Y., et al. Interventions for post-stroke fatigue. Cochrane Database Syst Rev. 2015 Jul 2; 2015 (7): CD007030. DOI: 10.1002/14651858.CD007030.pub3Немкова С.А., Семенов Д.А., Логинова Е.М. и др. Когнитивные и психоэмоциональные нарушения у учащихся и преподавателей вузов: возможности коррекции с помощью препарата рекогнан (цитиколин). Журнал неврологии и психиатрии им. С.С. Корсакова. 2018; 118 (12): 11–18. https://doi.org/10.17116/jnevro201811812111Nemkova S. A., Semenov D. V., Petrova E. A., et al. Cognitive and emotional disorders in university students and teachers: the possibility of treatment with recognan (citicoline). S.S. Korsakov Journal of Neurology and Psychiatry = Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2018; 118 (12): 11–18. (In Russ.). https://doi.org/10.17116/jnevro201811812111Ивонина Н.А., Петров К.Б. Применение нейротропной терапии у молодых пациентов с постковидным синдромом. Журнал неврологии и психиатрии им. С.С. Корсакова. 2022; 122 (3): 1–5. https://doi.org/10.17116/jnevro20221220311Ivonina N.A., Petrov K.B. The use of neurotropic therapy in young patients with postcovid syndrome. S.S. Korsakov Journal of Neurology and Psychiatry = Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2022; 122 (3): 1–5. (In Russ.). https://doi.org/10.17116/jnevro20221220311

The authors declare that there are no conflicts of interest present.